Patent For HIV Drug Rejected

NEW DELHI:  The Indian Patent Office has rejected the grant of a patent for dolutegravir, a crucial HIV drug marketed by Viiv Healthcare, facilitating the entry of generics and expanding access to affordable, life-saving treatment. The decision, announced after a contentious nearly decade-long battle, follows the company’s patent application for the HIV treatment in 2007.
The company faced multiple pre-grant oppositions from Natco and various advocacy groups between 2013 and 2019, according to the order accessed by TOI. It led to the Patent Office rejecting the grant of a patent recently. Experts believe the ruling could serve as an example against the practice of “evergreening” patents, a practice that extends patent life through patenting of obvious forms and improvements of life-saving medicines. Over the next few years, with more players entering the market, the first-line HIV drug will likely be available at a fraction of the innovator price.
“I am of the opinion that claims are not patentable under Section 3(d) of the Act since no enhanced therapeutic efficacy has been demonstrated in the specification,” the order by Deputy Controller D Usha Rao said.

Viiv Healthcare, which is majority owned by GSK and has Pfizer and Shionogi as major shareholders, is focused on HIV therapies. In April 2014, the Medicines Patent Pool and ViiV Healthcare signed licensing agreements to accelerate access to dolutegravir, for adult and paediatric care.

Related Posts

  • Pharma
  • February 10, 2025
  • 89 views
DGFT Amends Standard Input Output Norms For Erythromycin Stearate Tablets

Mumbai:  The Directorate General of Foreign Trade (DGFT), under the ministry of commerce & industry, has announced amendments to the Standard Input Output Norms (SION) for the export of erythromycin…

  • Pharma
  • February 10, 2025
  • 96 views
CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

THIRUVANANTHAPURAM: CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) in Thiruvananthapuram has developed a technology that converts pathogenic biomedical waste into value-added soil additives that eliminate the need for costly…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

An Index To Gauge States For Drug Enforcement, Improve Drug Quality

An Index To Gauge States For Drug Enforcement, Improve Drug Quality

DGFT Amends Standard Input Output Norms For Erythromycin Stearate Tablets

DGFT Amends Standard Input Output Norms For Erythromycin Stearate Tablets

CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

As Always Ahead of Game in healthcare, Doc was first to vote too

As Always Ahead of Game in healthcare, Doc was first to vote too

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister